
News|Articles|November 1, 2008
Labeling updates and warnings through November 2008 for efalizumab (Raptiva)
Labeling updates and warnings through November 2008 for efalizumab (Raptiva)
Advertisement
A boxed warning has been added to the labeling information for efalizumab (Raptiva, Genentech), which is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This warning highlights the risk of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), occurring in patients treated with efalizumab. Infections that have been observed in efalizumab-treated patients include bacterial sepsis, viral meningitis, invasive fungal disease, PML, and other opportunistic infections.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Zepbound linked to lower healthcare costs in older adults with obesity
2
Biosimilars provide modest cost savings for cancer patients, study finds
3
On Medicaid work requirements, the end of ACA enhanced subsidies and ACAP’s 25th anniversary
4
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
5

























